Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: U of Toronto, Lumencor, U of California, Affymetrix, Leica Biosystems, PerkinElmer

Premium

Title: Droplet-based cell culture and cell assays using digital microfluidics.
Patent Number: 8,728,291
Filed: Jan. 11, 2013
Lead Inventor: Aaron Wheeler, University of Toronto


Title: Bioanalytical instrumentation using a light source subsystem.
Patent Number: 8,728,339
Filed: June 1, 2012
Lead Inventor: Claudia Jaffe, Lumencor


Title: Peptide microarray and method of use.
Patent Number: 8,728,980
Filed: Nov. 1, 2012
Lead Inventor: Wei Wang, University of California


Title: Parallel preparation of high fidelity probes in an array format.
Patent Number: 8,729,251
Filed: Nov. 20, 2012
Lead Inventor: Robert Kuimelis, Affymetrix


Title: Data management in a linear-array-based microscope slide scanner.
Patent Number: 8,731,260
Filed: Jan. 10, 2012
Lead Inventor: Greg Crandall, Leica Biosystems


Title: Web-based genetics analysis.
Patent Number: 8,731,956
Filed: Nov. 5, 2008
Lead Inventor: Bassem Bejjani, Signature Genomic Laboratories (now PerkinElmer)

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.